EUH Hunt Conference: What is the prognosis for adenocarcinoma of the lung?

The Bottom Line: There is an overall survival rate of less than 5 years.

  • Stage I: 68-92%
  • Stage II: 53-60%
  • Stage III: 13-36%
  • Stage IV: 0-10%

Reference: DynaMed Plus [Internet]. Ipswich (MA): EBSCO Information Services. 1995 – . Record No. 114774, Non-small cell lung cancer; [updated 2018 May 01, cited 15 May 2018]; [about 31 screens]. Emory access required.

Summary: Five-year survival is only 5-8% in patients with unresectable NSCL cancer. Patients with untreated T1 tumors have a survival rate of 9%. Five-year mortality is higher in men than in women.

5-year survival for patients with lung and bronchus cancer by stage at diagnosis:

  • 18% with disease at all stages
  • 55% with localized disease
  • 28% with regional disease
  • 4% with distant stage disease

A study considering intervention and age found that older age and less intervention is associated with poorer survival:

  • > 80 years: 47% no radiation/surgery, 7.4% 5-year survival
  • 70-79 years: 28% no radiation/surgery, 12.3% 5-year survival
  • < 70 years: 19% no radiation/surgery, 15.5% 5-year survival

Additional Information: DynaMed Plus provides breakdowns by stage, age, and other factors.

For information on the staging of lung cancer, see the IASLC Lung Cancer Staging Project.

This entry was posted in EUH, Prognosis, Teaching pearls. Bookmark the permalink.